Xalkori/ALKThis case study highlights the importance of co-development and co-approval processes to achieve rapid approval of both the test and therapy. Using Xalkori and the development of an ALK test as an example, the case study recommends communications strategies are put in place to communicate with payers about the cost of the test. It will help you understand:
- That co-development of the anaplastic lymphoma kinase (ALK) test was pivotal for a successful launch of Xalkori by Pfizer
- How the cost of a test can be a major issue for payers and patients
- How test technology can influence a test's adoption and prescribing rates
- How, during the six months in the market since receiving FDA approval, the ALK mutation test enjoyed a fast adoption.